Selecta Biosciences, Inc.
-
Ticker
SELB
-
Industry
Biotechnology More
-
Sector
Healthcare More
- 11-50 Employees
- Based in Watertown, Massachusetts
Selecta Biosciences Inc. (NASDAQ: SELB) is leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses. With a proven ability to induce tolerance to highly immunogenic proteins, ImmTOR has the potential to amplify the efficacy of biologic therapies, including redosing of life-saving gene therapies, as well as
…More restore the body’s natural self-tolerance in autoimmune diseases. The company’s first program aimed at addressing immunogenicity to AAV gene therapies is expected to enter clinical trials in early 2021 in partnership with AskBio for the treatment of methylmalonic acidemia (MMA), a rare metabolic disorder. A wholly-owned program focused on addressing IgA nephropathy driven by ImmTOR and a therapeutic enzyme is also in development among additional product candidates. Selecta recently licensed its Phase 3 clinical product candidate, SEL-212, in chronic refractory gout to Sobi.
REPORT RATINGS
4.8 / 5.0 (174)
Selecta Biosciences, Inc. reports have an aggregate usefulness score of 4.8 based on 174 reviews.
Selecta Biosciences, Inc.
Most Recent Annual Report
MOST RECENT
2022 Annual Report and Form 10K
Older/Archived Annual Reports